SecSonar.com

Repligen Corporation (RGEN)

Repligen Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Repligen Corporation (RGEN) is a Medical - Instruments & Supplies company based in US with a market capitalization of $7.1B. Revenue grew 16.4% year-over-year and the company generated $93.9M in free cash flow. This page tracks RGEN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 1.78K employees · IPO Apr 29, 1986

Valuation

Valuation & price

$102.87 · as of May 17, 2026 · -40.3% vs 52w high

119.0

P/E ratio

Latest-FY diluted EPS

3.35

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$172$138$103Jul 25Dec 25Jul 26Jul 7, 25$124.43Jul 9, 25$129.82Jul 11, 25$130.19Jul 15, 25$118.10Jul 17, 25$124.04Jul 21, 25$114.80Jul 23, 25$117.13Jul 25, 25$121.74Jul 29, 25$125.30Jul 31, 25$117.07Aug 4, 25$116.50Aug 6, 25$112.10Aug 11, 25$111.88Aug 13, 25$127.15Aug 15, 25$124.35Aug 19, 25$123.50Aug 21, 25$119.65Aug 25, 25$121.26Aug 27, 25$118.88Aug 29, 25$122.32Sep 3, 25$116.18Sep 5, 25$124.56Sep 9, 25$118.69Sep 11, 25$119.51Sep 16, 25$119.75Sep 18, 25$124.38Sep 22, 25$125.94Sep 24, 25$124.51Sep 26, 25$125.61Sep 30, 25$133.67Oct 2, 25$145.23Oct 6, 25$150.10Oct 8, 25$150.81Oct 10, 25$145.24Oct 14, 25$148.40Oct 16, 25$154.55Oct 21, 25$156.75Oct 23, 25$165.20Oct 27, 25$161.10Oct 29, 25$148.48Oct 31, 25$149.06Nov 4, 25$146.93Nov 6, 25$144.98Nov 10, 25$145.66Nov 12, 25$158.01Nov 14, 25$152.37Nov 18, 25$153.06Nov 20, 25$154.36Nov 25, 25$171.76Nov 28, 25$171.02Dec 2, 25$165.02Dec 4, 25$165.76Dec 8, 25$160.81Dec 10, 25$163.80Dec 12, 25$157.39Dec 16, 25$158.09Dec 18, 25$157.72Dec 22, 25$165.58Dec 24, 25$165.66Dec 29, 25$165.73Jan 2, 26$164.35Jan 6, 26$172.26Jan 8, 26$166.42Jan 12, 26$168.40Jan 14, 26$162.03Jan 16, 26$162.02Jan 21, 26$169.97Jan 23, 26$162.33Jan 27, 26$163.63Jan 29, 26$156.37Feb 2, 26$151.12Feb 4, 26$146.11Feb 9, 26$143.58Feb 11, 26$139.40Feb 13, 26$136.44Feb 18, 26$138.11Feb 20, 26$135.68Feb 24, 26$134.67Feb 26, 26$133.65Mar 2, 26$124.97Mar 4, 26$125.84Mar 6, 26$119.99Mar 10, 26$121.79Mar 12, 26$113.76Mar 17, 26$119.27Mar 19, 26$117.61Mar 23, 26$116.35Mar 25, 26$114.32Mar 27, 26$110.12Mar 31, 26$117.82Apr 2, 26$117.78Apr 7, 26$115.29Apr 9, 26$119.78Apr 13, 26$122.59Apr 15, 26$131.93Apr 17, 26$131.21Apr 22, 26$124.40Apr 24, 26$117.60Apr 28, 26$117.43Apr 30, 26$118.31May 4, 26$118.21May 6, 26$125.76May 8, 26$123.46May 12, 26$113.60May 14, 26$103.38May 18, 26$104.20May 20, 26$111.74May 22, 26$115.06May 28, 26$122.73Jun 1, 26$123.10Jun 3, 26$121.73Jun 5, 26$122.31Jun 9, 26$130.13Jun 11, 26$133.33Jun 15, 26$130.87Jun 17, 26$133.55Jun 22, 26$126.57Jun 24, 26$138.40Jun 26, 26$147.01Jul 2, 26$142.40
$102.8752-week range$172.26
Loading valuation history…

Fundamentals

Key fundamentals

$7.1B

Market cap

16.4%

Revenue growth (YoY)

47.1%

Gross margin

$93.9M

Free cash flow (USD)

-$77.7M

Net debt

Net cash position

0.5%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$104.5MFY 2017$141.2MFY 2018$194.0MFY 2019$270.2MFY 2020$366.3MFY 2021$670.5MFY 2022$801.5MFY 2023$632.4MFY 2024$634.4MFY 2025$738.3M
$104.5M$738.3M

Free cash flow by year

2016 → 2025

FY 2016$3.2MFY 2017$12.0MFY 2018$18.7MFY 2019$44.1MFY 2020$36.3MFY 2021$47.7MFY 2022$38.7MFY 2023$74.9MFY 2024$142.5MFY 2025$93.9M
$3.2M$93.9M

Gross margin by year

2021 → 2025

FY 202158.4%FY 202256.9%FY 202344.0%FY 202443.3%FY 202547.1%
58.4%47.1%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $106K · 10b5-1 PlanGarland Jason K · CFO · $106.3KJun 26, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 15, 2026Filing
  • Quarterly report10-Q FiledMay 6, 2026Filing
  • 8-K eventEarnings ReleaseMay 5, 2026Filing

Questions

Frequently asked questions

What is Repligen Corporation's market cap?

Repligen Corporation (RGEN) has a market capitalization of $7.1B.

What is RGEN's P/E ratio?

RGEN trades at a price-to-earnings ratio of 119.0, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is RGEN's price-to-book (P/B) ratio?

RGEN trades at 3.35 times book value per share.

Are insiders buying RGEN stock?

SEC Form 4 filings show no open-market insider buys at Repligen Corporation in the last 90 days (1 sell).

Same arena

Related companies in Medical - Instruments & Supplies

ATR

AptarGroup, Inc.

$7.4B

AVTR

Avantor, Inc.

$6.4B

TFX

Teleflex Incorporated

$5.7B

STVN

Stevanato Group S.p.A.

$5.2B

BAX

Baxter International Inc.

$9.8B

MMSI

Merit Medical Systems, Inc.

$3.8B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.